Chronic Kidney Disease

Patients with chronic kidney disease (CKD) and type 2 diabetes receiving both treatments had greater reductions in urinary albumin-to-creatinine ratio.

Vadadustat and darbepoetin alfa show similar safety and efficacy in treating CKD-related anemia, with regional differences impacting cardiovascular risks.

Researchers explore cellular senescence's role in kidney fibrosis, highlighting potential therapies to combat chronic kidney disease progression.

CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice.

The investigators suggest that early detection and treatment of chronic kidney disease (CKD) in childhood cancer survivors may decrease late complications and mortality.

After 3 predictive mortality tools demonstrate inefficiency within older adults with advanced chronic kidney disease (CKD), the authors call for the development of tools tailored for this population.

Specialty pharmacists enhance CKD management through personalized care, medication adherence strategies, and collaboration with health care providers.

In approximately 84% of cases, the mask was able to detect if patients had chronic kidney disease (CKD).

The condition, which is common in patients with chronic kidney disease (CKD), is characterized by skin lesions and currently has no curative treatment.

This component of scar tissue may have a role in kidney fibrosis for slowing disease progression and improving outcomes for patients with chronic kidney disease (CKD).

At 28 to 179 days, COVID-19 infection in patients with preexisting chronic kidney disease (CKD) was associated with an increased risk of composite kidney events.

In patients with CKD, there were negative associations between the sodium cotransporter (NCC) and its phosphorylation (pNCC) in urinary extracellular vesicles (uEVs), but further research is needed to confirm these findings in a larger cohort.

Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.

Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.

In certain patients with chronic kidney disease (CKD), peritoneal dialysis maintained hemodynamic stability, optimal nutritional status, reduced hospitalization, and lowered diuretics reliance.

Some of these approaches for chronic kidney disease (CKD) include cystatin C, SGLT2 inhibitors, point-of-care testing in remote areas, and acid-lowering medications.

The treatment's expanded indication for chronic kidney disease (CKD) is expected to be available by April 2025.

Additional risk factors included older age and advanced chronic kidney disease (CKD) stage.

Clinical decision support systems based on algorithms have improved outcomes and reduced costs in other health care settings.

The authors suggest future research should consider inflammation and the gut as potential therapeutic targets improve depression in patients with chronic kidney disease (CKD).

Reductions in cerebellar volume were associated with cognitive deficits and lower kidney function in those with CKD.

These findings can lay the foundation for the development of machine learning models in chronic kidney disease (CKD) and kidney failure.

ABO-101 is supported by preclinical data that demonstrated significant reductions in urinary oxalate in PH1 disease models.

Some risk factors for chronic kidney disease (CKD) in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) were renal impairment, delayed diagnosis, and hypertension.

Statin use is not associated with a change in incident chronic kidney disease (CKD) and estimated glomerular filtration rate in adult patients aged 65 and older.

The authors note that transferrin saturation levels may be a modifiable risk factor of chronic kidney disease (CKD) progression and all-cause mortality.

The new indication for semaglutide adds to the long list of conditions that the GLP-1 receptor agonist has been approved for, and provides a new option for high-risk patients with these chronic conditions.

The reduction in cardiovascular end points and the increase in adverse events observed in a clinical trial were largely transportable to trial-eligible chronic kidney disease (CKD) populations from clinical practice.

Patients with methotrexate (MTX)-induced acute kidney injury treated with glucarpidase were 2.70-times more likely to have kidney recovery and recover faster.

The Kidney Disease: Improving Global Outcomes guidelines can provide pharmacists with approaches to minimizing chronic kidney disease progression and complications.